Statin wars - Emphasis on potency vs event reduction and safety?

Mayo Clinic Proceedings

Volumn 82, Issue 5, 2007, Pages 539-542

  Lavie, Carl J ^a   Milani, Richard V ^a   O'Keefe, James H ^b  

^a OCHSNER MEDICAL CENTER   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OMEPRAZOLE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EDITORIAL; HEMATURIA; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MONOTHERAPY; MYOPATHY; PROTEINURIA; RHABDOMYOLYSIS; SIDE EFFECT; STROKE; THROMBOCYTE FUNCTION;

EID: 34248159606     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.5.539     Document Type: Editorial

References (26)

1. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
2. LaRosa JC, Grundy SM, Waters DD et al, Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
3. Wiviott SD, Cannon CP, Morrow DA, Ray II, Pfeffer MA, Braunwald E, PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? the safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy [published correction appears in J Am Coll Cardiol. 2006;47:472]. J Am Coll Cardiol. 2005;46:1411-1416.
4. Grundy SM, Cleeman JI, Merz CN, et al, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment III guidelines [published correction appears in Circulation. 2004;110:763]. Circulation. 2004;110:227-239.
5. Insull W Jr, Ghali JK, Hassman DR, Yeas JW, Gandhi SK, Miller E. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007;82:543-550.
6. Jones PH, Davidson MH, Stein EA, et al, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003; 92:152-160.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82:128]. Am J Cardiol. 1998;81:582-587.
8. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease - is it time to shift our goals? [editorial]. N Engl J Med. 2005 Apr 7;352:1483-1484. Epub 2005 Mar 8.
9. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22:2041-2053.
10. Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci. 2005;330:295-302.
11. Lavie CJ, Milani RV. Lipid therapy in the elderly - emphasis on clinical event reduction and safety. Am J Geriatr Cardiol. 2006;15:245-247.
12. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007 Mar 13;49:1035-1042. Epub 2007 Feb 23.
13. Kontos MC, Joyner SE, Roberts CS, et al. Implication of the new low-density lipoprotein goals in dyslipidemia management of patients with acute coronary syndrome. Mayo Clin Proc. 2007;82:551-555.
14. Waters DD, Schwartz GG, Olsson AG, et al, MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002; 106:1690-1695.
15. de Lemos JA, Blazing MA, Wiviott SD, et al, A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
16. Ridker PM, Cannon CP, Morrow D, et al, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
17. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study [published correction appears in Am Heart J. 2005;149:882]. Am Heart J. 2005;149:464-473.
18. Ballantyne CM, Weiss R, Moccetti T, et al, EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER Study). Am J Cardiol. 2007 Mar 1;99:673-680. Epub 2007 Jan 4.
19. Ballantyne CM, Houri J, Notarbartolo A, et al, Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.
20. Bottorff MB. Statin safety: what to know. Am J Geriatr Cardiol. 2004; 13(3, suppl 1):34-38.
21. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc. 2005;80:1163-1168.
22. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol. 2005;96(5A):69F-75F.
23. Lavie CJ. Assessment and treatment of lipids in elderly persons [editorial] . Am J Geriatr Cardiol. 2004;13(3, suppl 1):2-3.
24. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005 Jun 14;111:3051-3057. Epub 2005 May 23.
25. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17;97(8A):89C-94C. Epub 2006 Feb 28.
26. Kasiske BL, Wanner C, O'Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol. 2006 Apr 17;97(8A):82C-85C. Epub 2006 Feb 9.